The approval expands options for protecting infants from respiratory syncytial virus, which remains a leading cause of pediatric hospitalization.
Kevin Chamberlin, PharmD, FASCP
Advertisement
Kevin Chamberlin, PharmD, FASCP, is the associate vice president and chief pharmacy officer at UConn Health John Dempsey Hospital in Farmington, Connecticut.
Articles by Kevin Chamberlin, PharmD, FASCP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in Infants
2
How Pharmacies’ Ability to Provide Behavioral Health Services is Growing | NCPA 2025
3
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
4
Pharmacy Technology Should Focus on Patient Engagement, Peer Insight | NCPA 2025
5
